Presentation by TinnOff in the MoneyTalks Espoo event on the 30th of August, 2012.

1. /Tinnoff2.0
antti.koivula@tinnoff.com
+358 40 718 3819
www.tinnoff.com
/maladaptive_neuroscience
/intelligent_cloud
/always_on-line_devices
/customized_self-care

2. Inside-Your-Brain

3. Status
/ Version 1.0 of E2E architechture ramped up
/ Advanced consumer testing on-going:
•Solid results from longitudial study of manual acustic
theraphy with 16 tinnitus patients
•Vagal nerve stimulation path proven with MEG
•Back-end fine-tuning on-going with >100 users
•Proof of concept of automated acustic theraphy
started with 30 tinnitus patients
•Piloting advanced stand-alone tVNS
/ Prioritizing the business model:
•Tinnitus to stay in clinical research
•Neurogenetic relaxation ramping up

5. Current Focus Investor Focus
Key customer Competitive Macro market
segments power positions attractiveness
web savvyness IPR portfolio economic
demand
tinnitus severinity company strenght structural entry barriers
/ key segments & proof of concept / IPR strategy & updates / market forecast
/ balance between virtual & physical channels / key competitors summary / go-to-market priorities
/ strategy
Updated Tinnoff business plan / long-range financial plan
/ investment plan
Q3 2012 ###
Q1 2013 ###
Tinnoff investor brief

6. Summary
Global market Provisionally
opportunity protected
technology
Promising Balanced core
business case team

7. Discussion
/maladaptive_neuroscience
/intelligent_cloud
/always_on-line_devices
/customized_self-care